Biosynthesis and synthetic biology of psychoactive natural products.
Cooper S Jamieson, Joshua Misa, Yi Tang, John M Billingsley
Chemical Society reviews June 1, 2021 DOI: 10.1039/d1cs00065a (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Review Peer reviewed |
|---|---|
| Keywords | Psychotropic drugs Biological products Molecular structure |
| Key findings | The authors review progress toward elucidating biosynthetic pathways for hallucinogens, stimulants, cannabinoids, and opioids, noting that genomic and molecular biology tools have enabled identification of genes encoding individual biosynthetic enzymes. They argue that these pathways are often comparable to organic syntheses in elegance and yield, and that the enzymes can be repurposed for synthetic biology and metabolic engineering, including heterologous production. |
Abstract
Psychoactive natural products play an integral role in the modern world. The tremendous structural complexity displayed by such molecules confers diverse biological activities of significant medicinal value and sociocultural impact. Accordingly, in the last two centuries, immense effort has been devoted towards establishing how plants, animals, and fungi synthesize complex natural products from simple metabolic precursors. The recent explosion of genomics data and molecular biology tools has enabled the identification of genes encoding proteins that catalyze individual biosynthetic steps. Once fully elucidated, the "biosynthetic pathways" are often comparable to organic syntheses in elegance and yield. Additionally, the discovery of biosynthetic enzymes provides powerful catalysts which may be repurposed for synthetic biology applications, or implemented with chemoenzymatic synthetic approaches. In this review, we discuss the progress that has been made toward biosynthetic pathway elucidation amongst four classes of psychoactive natural products: hallucinogens, stimulants, cannabinoids, and opioids. Compounds of diverse biosynthetic origin - terpene, amino acid, polyketide - are identified, and notable mechanisms of key scaffold transforming steps are highlighted. We also provide a description of subsequent applications of the biosynthetic machinery, with an emphasis placed on the synthetic biology and metabolic engineering strategies enabling heterologous production.
Citations in the library
Cited by 9
- A journey with psychedelic mushrooms: From historical relevance to biology, cultivation, medicinal uses, biotechnology, and beyond Biotechnology Advances August 31, 2023
- Effects of hallucinogenic drugs on the human heart Frontiers in Pharmacology February 2, 2024
- A mechanistic insight for the biosynthesis of N,N-dimethyltryptamine: An ONIOM theoretical approach. Biochemical and Biophysical Research Communications October 20, 2023
- Pathway engineering for the biosynthesis of psychedelics Current Opinion in Biotechnology May 15, 2025
- Unveiling the Psychedelic Journey: An Appraisal of Psilocybin as a Profound Antidepressant Therapy. Molecular biotechnology 2025
and 4 more in the library
Cites 60
- Pilot Study of Psilocybin Treatment for Anxiety in Patients With Advanced-Stage Cancer Archives of General Psychiatry September 7, 2010
- Psychedelics Promote Structural and Functional Neural Plasticity Cell Reports June 1, 2018
- Psilocybin with psychological support for treatment-resistant depression: six-month follow-up. Psychopharmacology November 8, 2017
- Pilot study of the 5-HT2AR agonist psilocybin in the treatment of tobacco addiction Journal of Psychopharmacology September 11, 2014
- Salvinorin A: a potent naturally occurring nonnitrogenous kappa opioid selective agonist. Proceedings of the National Academy of Sciences September 3, 2002
and 55 more in the library